Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Rating of "Buy" by Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine analysts that are covering the firm, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $62.50.

A number of research firms have recently commented on JSPR. Royal Bank of Canada decreased their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a report on Thursday, January 9th. JMP Securities reiterated a "market outperform" rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Finally, UBS Group started coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $38.00 price objective for the company.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its stake in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock worth $47,000 after purchasing an additional 1,698 shares during the period. Wells Fargo & Company MN increased its stake in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock valued at $159,000 after purchasing an additional 3,828 shares in the last quarter. EntryPoint Capital LLC bought a new stake in shares of Jasper Therapeutics in the 4th quarter worth approximately $223,000. Jane Street Group LLC purchased a new stake in shares of Jasper Therapeutics in the 3rd quarter worth approximately $251,000. Finally, Tema Etfs LLC purchased a new position in Jasper Therapeutics during the fourth quarter valued at $266,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Stock Down 3.4 %

Jasper Therapeutics stock traded down $0.15 during midday trading on Friday, hitting $4.09. 5,920 shares of the stock were exchanged, compared to its average volume of 281,667. The stock has a market capitalization of $61.36 million, a price-to-earnings ratio of -0.87 and a beta of 2.55. Jasper Therapeutics has a 52-week low of $3.13 and a 52-week high of $26.84. The business's 50-day moving average price is $5.08 and its 200-day moving average price is $13.09.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.35). On average, sell-side analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.